Wockhardt UK today announced a collaboration with Serum Life Sciences UK, a subsidiary of Serum Institute of India, the world’s largest vaccine manufacturer, to deliver a global vaccine programme for the supply of a wide range of vaccines.
This collaboration involves manufacturing of a number of vaccines at the Wockhardt UK site in North Wales. A profit sharing arrangement has been agreed between the two parties for this new facility which will help create a considerable number of employment opportunities along with creation of new sterile facility in Wrexham, North Wales.
This new facility will deliver an additional 150 million vaccine doses of multiple vaccines.
Wockhardt UK has manufactured a COVID-19 vaccine in collaboration with UK Government and AstraZeneca. Its collaboration with Serum Life Sciences UK is an addition to the earlier arrangement.
Media Enquiries Wockhardt UK
Media enquiries Wockhardt HQ India